Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-23

Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis [Phase 2]

View source ↗

Summary

Phase 2 study of LY3016859 in osteoarthritis completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY3016859

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoarthritis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-23